5 Patients Randomized
A vTv Therapeutics study site enrolled 5 patients into a Phase III T1D study across two site locations, with a contractual randomization commitment at each engagement.
Book a Free Consultation5
Patients Randomized
$12,500
Campaign Investment
$2,500
Cost Per Randomized Patient
A Phase III Requirement in a Condition With a Narrow Patient Profile
A vTv Therapeutics study site was running a Phase III trial of cadisegliatin as adjunctive therapy to insulin in participants with Type 1 Diabetes Mellitus, with specific eligibility requirements tied to diagnosis history and current treatment protocol.
The addressable patient pool for a T1D study on insulin is smaller than many Phase III indications. The site needed a recruitment partner who had evaluated the feasibility math before committing, not one who would invoice for activity while the enrollment gap widened.
The site needed referrals pre-screened against T1D-specific criteria and a contractual commitment that matched the site's accountability to the sponsor.
Feasibility Confirmed. Commitment Extended. Campaign Deployed.
Clinical Enroll evaluated the T1D protocol for feasibility before any campaign work began, modeling the addressable patient population, eligibility criteria complexity, and per-site enrollment targets. The commitment was confirmed supportable and formalized in contract. An IRB-compliant campaign was built and deployed across condition-targeted digital channels, with a pre-screening questionnaire aligned to the study's inclusion and exclusion criteria. Patients who did not meet the T1D-specific threshold were not referred.
5 Randomized Patients. Two Site Locations.
The campaign delivered 5 randomized patients across two site locations against a combined $12,500 investment, a cost per randomized patient of $2,500.
This was the first of several campaigns Clinical Enroll has run for this site. Repeat engagements don't happen when the first one underperforms.
Per-patient site fees for Phase III studies typically range from $8,000 to $20,000 per randomized patient depending on indication and protocol complexity. At an estimated $8,000 to $20,000 per-patient site fee, 5 randomized patients represents a potential $40,000 to $100,000 in patient revenue against a $12,500 campaign investment.
POTENTIAL ROI
$12,500
Campaign investment
$8k–$20k
Per-patient site fee range
$40k–$100k
Potential patient revenue
See if our guaranteed approach is the right fit for your study.
Narrow-eligibility protocols require a recruitment partner who has thought through the pre-screening math before committing. Book a free consultation to discuss your study and see if our guaranteed approach fits.
All campaigns developed for IRB review and deployed in accordance with FDA guidance on clinical trial advertising.